Cargando…
Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma
Glioblastoma is the most common primary brain malignancy and carries with it a poor prognosis. New agents are urgently needed, however nearly all Phase III trials of GBM patients of the past 25 years have failed to demonstrate improvement in outcomes. In 2019, the National Cancer Institute Clinical...
Autores principales: | Degorre, Charlotte, Tofilon, Philip, Camphausen, Kevin, Mathen, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480070/ https://www.ncbi.nlm.nih.gov/pubmed/34583727 http://dx.doi.org/10.1186/s13014-021-01918-y |
Ejemplares similares
-
Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization
por: Rath, Barbara H, et al.
Publicado: (2015) -
Glioblastoma cells have increased capacity to repair radiation-induced DNA damage after migration to the olfactory bulb
por: Degorre, Charlotte, et al.
Publicado: (2022) -
Translation Initiation Machinery as a Tumor Selective Target for Radiosensitization
por: Lehman, Stacey L., et al.
Publicado: (2021) -
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
por: Shabason, Jacob E, et al.
Publicado: (2011) -
Radiosensitization by the novel DNA intercalating agent vosaroxin
por: Gordon, Ira K, et al.
Publicado: (2012)